Strategies for cancer gene therapy using adenoviral vectors. 1996

V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
Génétique des virus oncogènes, Institut Gustave Roussy, Villejuif, France.

Modification of tumor cells using gene transfer either to enhance host immunity or to act directly on tumor cells is being intensively studied in animal models. Remarkable results have yielded to approved clinical protocols in the treatment of cancer patients using this approach. Several methods of gene delivery have been developed. This article is particularly devoted to the interest of the use of adenoviral vectors in the different strategies of cancer gene therapy.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000256 Adenoviridae A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. Adenoviruses,Ichtadenovirus,Adenovirus,Ichtadenoviruses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic

Related Publications

V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
August 2018, Clinics (Sao Paulo, Brazil),
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
December 1994, Current opinion in biotechnology,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
January 1998, Advances in experimental medicine and biology,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
July 1998, Primary care update for Ob/Gyns,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
May 2007, Molecular biotechnology,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
November 2000, The Lancet. Oncology,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
August 1997, International journal of oncology,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
October 2010, Viruses,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
April 2004, Seminars in thrombosis and hemostasis,
V Descamps, and M T Duffour, and M C Mathieu, and N Fernandez, and L Cordier, and M A Abina, and E Kremer, and M Perricaudet, and H Haddada
January 2004, Viral immunology,
Copied contents to your clipboard!